June 2016

Contents

Editorial

• May/June 2016: Volume 17 Number 5/6

In memory

• In Memory: Paul Blanchard, cofounder HIV i-Base

Treatment alerts

• NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos

Conference reports

• 22nd Annual BHIVA Conference, 19-22 April 2016, Manchester

• New HBV drugs and non-viral liver disease in HIV positive people

• Non-AIDS mortality in England and Wales in HIV positive vs general population

• High prevalence of multiple high-risk HPV infections in young HIV positive gay men

• Anal cancer and HPV screening in HIV positive people

• Increasing demand for community treatment information services

• Non alcohol fatty acid liver disease: an emerging problem

• HIV positive people on ART have impaired alveolar immunity

• International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona

• High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries

• Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries

• 23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston

• No effect of tenofovir on infant bone mineral content in African study

• Use of modelling to predicting paediatric dosing of long acting antiretrovirals

• Nevirapine dosing for treatment of neonates

• START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers

• Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV

• 6th International Workshop on HIV & Women, 20-21 February 2016, Boston

• Doravirine can be co-administered with oral contraceptives

• No increased risk of birth defects with darunavir: findings from the Antiretroviral Pregnancy Registry

Antiretrovirals

• FTC/TAF dual-nuke approved in the US and Europe

• Paediatric labeling expanded, and additional tablet strengths for FTC/TDF

Treatment access

• Timeline for access to generic dolutegravir: what still needs to be done

• Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART

• South Africa takes bold step to provide HIV treatment for all

Side effects

• Persistent HPV infection may be related to tissue type in HIV positive people

On the web

• Community reports

PDFs

• May/June 2016: Volume 17 Number 5/6